Biweekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients

• Published in: Gan to kagaku ryoho Vol. 33; no. 8; p. 1081
• Main Authors: Kagawa, Naoki, Fukuda, Yasuhiko, Arai, Haruka, Sasada, Tatsunari, Yamashita, Masahiro, Komekami, Yusuke, Matsugu, Yasuhiro, Nakahara, Hideki, Tanaka, Tsuneo
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.08.2006
• Subjects: Aged; Aged, 80 and over; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Prognosis; Receptor, ErbB-2 - biosynthesis; Remission Induction; Survival Rate; Taxoids - administration & dosage; Trastuzumab
• ISSN: 0385-0684

Docetaxel and trastuzumab can be considered to be active drugs for HER 2-overexpressing metastatic breast cancer (MBC). This study was conducted to determine the activity of combination therapy with docetaxel and trastuzumab in MBC patients by assessing the response rate (RR), time to progression (TTP) and safety. We administered the combination of docetaxel 30-40 mg/m(2) biweekly and trastuzumab using a 4 mg/kg loading dose and thereafter 2 mg/kg weekly. Between October 2001 and December 2004, 14 patients with HER 2 positive (3+ by immunohistochemistry) MBC were enrolled in this study. The overall RR was 50.0% (7/14), with 1 CR, 6 PR, 3 NC and 4 PD. Median follow-up time was 15.0 months, while the median TTP was 10.8 months,and the median OS 21.8 months.